Brand-name drug · melanocortin receptor agonist
Vyleesi (bremelanotide)
From the FDA label, read Published by PepVault
Vyleesi is bremelanotide, the peptide known in research as PT-141, sold by Cosette Pharmaceuticals as a single-dose autoinjector used only when needed.
FDA approved it for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or difficulty in a relationship and is not explained by another condition, relationship problems or a medicine.
- Active ingredient
- PT-141
- Maker
- Cosette Pharmaceuticals
- Class
- melanocortin receptor agonist
- FDA application
- NDA 210557, first approved 2019
What FDA approved it for
Acquired means the low desire began after a time without problems; generalized means it happens regardless of situation or partner. The label rules out postmenopausal women and men, and says Vyleesi is not for enhancing sexual performance.
From the label: 2.1 Recommended Dosage; 1 Indications and Usage.
How it is supplied
| Form | Doses |
|---|---|
| Single-dose autoinjector | 1.75 mg |
From the label: 3 Dosage Forms and Strengths.
The label’s dosing schedule
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Vyleesi, as needed
| Dose | When, on the label |
|---|---|
| 1.75 mg a dose | As needed, at least 45 minutes before sexual activity; at most one dose in 24 hours and 8 a month |
There is no climb: every dose is the same 1.75 mg, from the first. Few women in the trials used more than 8 doses a month, and the label adds that using it more often raises the chance of darkened skin patches and lengthens the time each month with raised blood pressure.
From the label: 2.1 Recommended Dosage.
How it’s taken
Vyleesi is injected under the skin of the belly or thigh when needed, at least 45 minutes before expected sexual activity. The label says how long each dose works is unknown, and leaves the timing to each woman’s own experience of it.
The limits are firm: no more than one dose in 24 hours, because doses close together may add to the rise in blood pressure, and no more than 8 doses a month.
If there is no improvement after 8 weeks, the label says to stop.
From the label: 2.1 Recommended Dosage; 2.2 Discontinuation of VYLEESI.

If a dose is missed
Vyleesi is used as needed, so its label has no missed-dose rule.
Storage
Vyleesi is stored at or below 77°F, out of light, and never frozen.
From the label: 16 How Supplied / Storage and Handling.
Side effects and warnings
| Reaction | Placebo | 1.75 mg |
|---|---|---|
| Nausea | 1.3 | 40.0 |
| Flushing | 0.3 | 20.3 |
| Injection site reactions | 8.4 | 13.2 |
| Headache | 1.9 | 11.3 |
| Vomiting | 0.2 | 4.8 |
| Cough | 1.3 | 3.3 |
| Fatigue | 0.5 | 3.2 |
| Hot flush | 0.2 | 2.7 |
Nausea was the most common reaction, in 40% against 1% on placebo; it usually began within an hour of the dose and lasted about two hours. In the trials, 18% stopped Vyleesi because of side effects, against 2% on placebo.
The other warnings
Vyleesi has no boxed warning. Its label warns that each dose briefly raises blood pressure and lowers heart rate, peaking 2 to 4 hours after the dose, so it is not for people with uncontrolled high blood pressure or known heart disease. It also warns of darkened patches of skin (focal hyperpigmentation) and of nausea, and says to avoid naltrexone taken by mouth, whose levels Vyleesi can lower.
From the label: 6.1 Clinical Trials Experience; 5 Warnings and Precautions.
What else we have on bremelanotide
Bremelanotide on PepVault
Free tools
The trials, in plain English
Compound against compound
Questions about Vyleesi
What is the dose of Vyleesi?
The label’s dose is 1.75 mg injected under the skin of the belly or thigh, as needed, at least 45 minutes before sexual activity. A prescriber decides whether it fits.
How often can Vyleesi be used?
No more than one dose in 24 hours and no more than 8 doses a month, according to the label.
Is Vyleesi the same as PT-141?
Vyleesi’s active ingredient is bremelanotide, the peptide known in research as PT-141; Vyleesi is the FDA-approved product made to its label.
What is the most common side effect of Vyleesi?
Nausea, in 40% of women in the trials against 1% on placebo, usually starting within an hour and lasting about two hours.
Is Vyleesi approved for men?
No. Its label says it is not for men or for postmenopausal women, and not for enhancing sexual performance.
Sources
- VYLEESI (bremelanotide injection), for subcutaneous use, FDA label on DailyMed (version 2, published Nov 9, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 210557 (Vyleesi, the autoinjector; application first approved 2019)
PepVault is not affiliated with Cosette Pharmaceuticals. Vyleesi is a trademark of its owner.